BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 38799236)

  • 21. Genotoxicity evaluation of nitrosamine impurities using human TK6 cells transduced with cytochrome P450s.
    Li X; He X; Le Y; Guo X; Bryant MS; Atrakchi AH; McGovern TJ; Davis-Bruno KL; Keire DA; Heflich RH; Mei N
    Arch Toxicol; 2022 Nov; 96(11):3077-3089. PubMed ID: 35882637
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of a Novel LC-MS/MS Based Analytical Method for the Risk Assessment of Nitrosamines in Pharmaceutical Products and Packaging Materials.
    Kartop RA; Güleli M; Faruzlu FA; Çalışkan C
    J Pharm Sci; 2024 Jun; 113(6):1597-1606. PubMed ID: 38253223
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevalence of nitrosamine contaminants in drug samples: Has the crisis been overcome?
    Schmidtsdorff S; Neumann J; Schmidt AH; Parr MK
    Arch Pharm (Weinheim); 2023 Feb; 356(2):e2200484. PubMed ID: 36461687
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Maximizing use of existing carcinogenicity data to support acceptable intake levels for mutagenic impurities in pharmaceuticals: Learnings from N-nitrosamine case studies.
    Felter SP; Ponting DJ; Mudd AM; Thomas R; Oliveira AAF
    Regul Toxicol Pharmacol; 2023 Sep; 143():105459. PubMed ID: 37474097
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Quantum Mechanical Assessment of Nitrosamine Potency.
    De S; Thapa B; Sayyed FB; Frank SA; Cornwell PD; Jolly RA
    Chem Res Toxicol; 2024 Jun; 37(6):1011-1022. PubMed ID: 38804898
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mutagenic impurities in pharmaceuticals: A critical assessment of the cohort of concern with a focus on N-nitrosamines.
    Snodin DJ
    Regul Toxicol Pharmacol; 2023 Jun; 141():105403. PubMed ID: 37116739
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of a Sensitive Screening Method for Simultaneous Determination of Nine Genotoxic Nitrosamines in Active Pharmaceutical Ingredients by GC-MS.
    Witkowska AB; Giebułtowicz J; Dąbrowska M; Stolarczyk EU
    Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36292981
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analytical lifecycle management for comprehensive and universal nitrosamine analysis in various pharmaceutical formulations by supercritical fluid chromatography.
    Schmidtsdorff S; Neumann J; Schmidt AH; Parr MK
    J Pharm Biomed Anal; 2021 Apr; 197():113960. PubMed ID: 33626447
    [TBL] [Abstract][Full Text] [Related]  

  • 29. GFP-fused yeast cells as whole-cell biosensors for genotoxicity evaluation of nitrosamines.
    He Y; Ding H; Xia X; Qi W; Wang H; Liu W; Zheng F
    Appl Microbiol Biotechnol; 2021 Jul; 105(13):5607-5616. PubMed ID: 34228183
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Performance Characteristics of Mass Spectrometry-Based Analytical Procedures for Quantitation of Nitrosamines in Pharmaceuticals: Insights from an Inter-laboratory Study.
    Yang J; Kakarla R; Marzan T; Sherwin B; George M; Bennett J; Basutto J; Su Y; Ollerenshaw J; Morin J; Rebière H; Maggio AF; Kermaïdic A; Gervela E; Brenier C; Civade C; Chauvey D; Duperray F; Wollein U; Conti M; Tromp J; Meyer S; Wanko R; Wierer M; Bertrand M; Rodriguez J; Sommers C; Keire D
    J Pharm Sci; 2023 Oct; 112(10):2685-2695. PubMed ID: 37524228
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Full Evaporation Static Headspace Gas Chromatography Method with Nitrogen Phosphorous Detection for Ultrasensitive Analysis of Semi-volatile Nitrosamines in Pharmaceutical Products.
    Zheng J; Kirkpatrick CL; Lee D; Han X; Martinez AI; Gallagher K; Evans RK; Mudur SV; Liang X; Drake J; Buhler LA; Mowery MD
    AAPS J; 2022 Jan; 24(1):23. PubMed ID: 34993666
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current Threat of Nitrosamines in Pharmaceuticals and Scientific Strategies for Risk Mitigation.
    Tuesuwan B; Vongsutilers V
    J Pharm Sci; 2023 May; 112(5):1192-1209. PubMed ID: 36739905
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Simultaneous analysis of carcinogenic N-nitrosamine impurities in metformin tablets using on-line in-tube solid-phase microextraction coupled with liquid chromatography-tandem mass spectrometry.
    Ishizaki A; Ozawa K; Kataoka H
    J Chromatogr A; 2023 Nov; 1710():464416. PubMed ID: 37804578
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Strategies for Assessing Acceptable Intakes for Novel
    Ponting DJ; Dobo KL; Kenyon MO; Kalgutkar AS
    J Med Chem; 2022 Dec; 65(23):15584-15607. PubMed ID: 36441966
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Multi-Analyte LC-MS/MS Method for Determination and Quantification of Six Nitrosamine Impurities in Sartans like Azilsartan, Valsartan, Telmisartan, Olmesartan, Losartan and Irbesartan.
    Gopireddy RR; Maruthapillai A; Mahapatra S
    J Chromatogr Sci; 2024 Feb; 62(2):147-167. PubMed ID: 35830866
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Regulatory Updates and Analytical Methodologies for Nitrosamine Impurities Detection in Sartans, Ranitidine, Nizatidine, and Metformin along with Sample Preparation Techniques.
    Shaik KM; Sarmah B; Wadekar GS; Kumar P
    Crit Rev Anal Chem; 2022; 52(1):53-71. PubMed ID: 32691615
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mechanisms of Nitrosamine Mutagenicity and Their Relationship to Rodent Carcinogenic Potency.
    Snodin DJ; Trejo-Martin A; Ponting DJ; Smith GF; Czich A; Cross K; Custer L; Elloway J; Greene N; Kalgutkar AS; Stalford SA; Tennant RE; Vock E; Zalewski A; Ziegler V; Dobo KL
    Chem Res Toxicol; 2024 Feb; 37(2):181-198. PubMed ID: 38316048
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modified NAP test: A simple and Responsive Nitrosating Methodology for Risk Evaluation of NDSRIs.
    Sharma N; Patel R; Bothara T; Jain S; Shah RP
    J Pharm Sci; 2023 May; 112(5):1333-1340. PubMed ID: 36871894
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Critical Analysis of Drug Product Recalls due to Nitrosamine Impurities.
    Bharate SS
    J Med Chem; 2021 Mar; 64(6):2923-2936. PubMed ID: 33706513
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comprehensive UHPLC-MS screening methods for the analysis of triazolopyrazine precursor and its genotoxic nitroso-derivative in sitagliptin pharmaceutical formulation.
    Jireš J; Douša M; Gibala P; Doubský J; Pěček D; Mervart D; Kluk A; Veseli A; Kalášek S; Řezanka P
    J Pharm Biomed Anal; 2024 Jan; 238():115861. PubMed ID: 37976984
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.